DFTX
Definium Therapeutics Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2015-05-04
$33.41
+0.94 (+2.89%)
last quote
Want the full multi-source brief on DFTX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$33.41
High
$34.62
Low
$32.73
Previous close
$32.47
Fundamentals
Market cap
$4.48B
P/E (TTM)
—
P/S (TTM)
—
P/B
4.04x
Gross margin
—
Operating margin
—
Net margin
—
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-85.23%
52W high
$49.70
52W low
$10.46
Beta
2.38x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-09in 4 daysafter market
Q3 2026EPS est $-0.57
Recent SEC filings
CIK 1813814filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 1d
Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, November 03, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:
Yahoo · 5d
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK, October 29, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended September
Benzinga · 5d
'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana' - Marijuana Moment
https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/
SeekingAlpha · 7d
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market
Compass Pathways is initially targeting the TRD market, which is large and underserved. Find out why CMPS stock is a Buy.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial